Trilogy Capital’s Xylem XYL Stock Holding History

Trilogy Capital’s Portfolio XYL Stock Details XYL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-583	Closed	-$47K	–	583
2018 Q3	$47K	Hold	583	–	–	0.01%	199
2018 Q2	$39K	Buy	583 +13	+2%	+$944	0.01%	199
2018 Q1	$44K	Buy	+570	New	+$42.1K	0.01%	172

Other funds holding XYL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Trilogy Capital's XYL Position: Q4 2018 in Review

Trilogy Capital sold out of Xylem (XYL) in Q4 2018, closing a stake of 583 shares — an estimated $47K sold.

Trilogy Capital first reported a position in XYL in Q1 2018 and held it in 3 quarters. The position peaked at $47K in Q3 2018. 644 funds tracked by Wall St. Rank hold XYL as of Q4 2018.

Trilogy Capital reported no remaining Xylem position as of Q4 2018 after selling out during the quarter.
Trilogy Capital sold 583 Xylem shares in Q4 2018, an estimated $47K.
Trilogy Capital first reported a position in Xylem in Q1 2018 and held it in 3 quarters.
Trilogy Capital's Xylem position peaked at $47K in Q3 2018.
644 funds tracked by Wall St. Rank held Xylem as of Q4 2018.

Based on Trilogy Capital's 13F filing for Q4 2018, filed 15 Jan 2019.